Site Editor

William J. Gradishar, MD, FACP, FASCO


Using Biomarkers to Predict Response to Immunotherapy in Breast Cancer: I-SPY2 Trial

By: Kayci Reyer
Posted: Thursday, July 20, 2023

An evaluation of biomarkers from the I-SPY2 trial, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 102), suggests that immune markers may predict response to immuno-oncology treatment in some types of breast cancer. The analysis found that biomarkers such as ImPrint, a 53-gene signature, and other tumor immune-signaling signatures may predict treatment response in both triple-negative and hormone receptor [HR]-positive, HER2-negative breast cancers.

“The ImPrint single-sample classifier predicts response to a variety of [immuno-oncology] regimens in both subsets and may inform prioritization of [immuno-oncology versus] other treatments and best balance likely benefit [versus] risk of serious immune-related adverse events,” according to Denise M. Wolf, PhD, of the University of California, San Francisco, and colleagues.

The evaluation included 343 patients with HER2-negative breast cancer who received treatment in one of five immuno-oncology therapy arms, plus 343 controls. Chemokine- and cytokine-heavy tumor-immune signatures demonstrated the most consistent association with pathologic complete response, regardless of therapy arm or receptor status. These markers were also associated with high spatial co-localization of PD-1–positive immune cells and PD-L1–positive tumor cells, according to multiplex immunofluorescence spatial proximity measurements. This was particularly evident among patients with triple-negative disease.

Across all therapy arms, ImPrint status was found to be linked to pathologic complete response rates, which were higher for patients harboring ImPrint markers (75% vs. 23%). Although lower than the overall therapy rates, pathologic complete response rates also remained higher for control group patients who were ImPrint-positive (34% vs. 13%).

Research-grade immune markers were more likely to predict response among patients with HR-positive disease than those with triple-negative disease. Associations between pathologic complete response and 32 continuous markers, 30 of which were immune markers, plus ESR1/PGR and proliferation signatures were determined using logistic regression.

Disclosure: Dr. Wolfe reported no conflicts of interest. For full disclosures of the other study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.